Blueprint Medicines Corporation Q2 revenuesChristian Fernsby ▼ | July 30, 2020
Blueprint Medicines Corporation reported financial results for the second quarter ended June 30, 2020.
Blueprint Medicines Corporation Revenues were $8.3 million for the second quarter of 2020
Topics: Blueprint Medicines Corporation
Cost of sales was $0.1 million for the second quarter of 2020. Blueprint Medicines did not incur cost of sales in the second quarter of 2019 as no product sales were generated during that period.
Net loss was $123.5 million for the second quarter of 2020 as compared to a net loss of $99.7 million for the second quarter of 2019.
As of June 30, 2020, cash, cash equivalents and investments were $650.3 million. ■